Bob Lanza

Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more

stem-cell-news-pigs-organ-transplants

What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses …

Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more Read More »

ACT reinventing itself with new name Ocata Therapeutics

advanced-cell-technology

Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently …

ACT reinventing itself with new name Ocata Therapeutics Read More »

ACT’s Bob Lanza Does the #IceBucketChallenge

Robert-Lanza

Before I did the #icebucketchallenge, I challenged the leader of Advanced Cell Technology (ACT), Dr. Bob Lanza, to do the Ice Bucket Challenge. He did it and leading up to it he provided a quite articulate message for context (see video below). Bob is one very cool guy even without ice water. The purpose of the …

ACT’s Bob Lanza Does the #IceBucketChallenge Read More »

Cloning is cloned again: New Nature Paper is 3rd on Human SCNT

Yamada-Extended-Data-SCNT

A new human therapeutic cloning paper is out today, the third in a matter of months. This one is from the lab group of Dr. Dieter Egli published in Nature demonstrating production of nuclear transfer embryonic stem cells (NT-ESCs) from an adult human somatic donor via somatic cell nuclear transfer (SCNT). This human SCNT paper follows …

Cloning is cloned again: New Nature Paper is 3rd on Human SCNT Read More »

Advanced Cell Technology (ACTC) announces plan to make iPS cell-derived platelets: some thoughts

Advanced Cell Technology (ACT) is well into clinical trials for macular degeneration (the leading cause of blindness) using human embryonic stem cell (hESC)-based retinal pigmented epithelial cells (RPE). To date, the trials suggest the products are safe. Efficacy? We don’t know. I am cautiously hopeful, but it is frustrating to know that most clinical trials …

Advanced Cell Technology (ACTC) announces plan to make iPS cell-derived platelets: some thoughts Read More »

Why I finally bought stock in Advanced Cell Technology

advanced-cell-technology

Today after years of following the company Advanced Cell Technology (ACT), I finally bought stock (ACTC) in it. Why? As a stem cell researcher myself working on human ES cells, iPS cells, and many other types of stem cells, I have been following ACT for years, but have never pulled the trigger to buy their stock….until …

Why I finally bought stock in Advanced Cell Technology Read More »